Predicting responses to androgen deprivation therapy

A method for identifying a prostate cancer patient likely to survive death related to prostate cancer for a time longer than 3.5 years, wherein said method comprises:

• (a) detecting the presence of a UGT1A3 allele comprising rs17864701, rs17862875, or rs11891311 in said patient, and
• (b) classifying said patient as being likely to survive death related to prostate cancer for a time longer than 3.5 years based at least in part on the presence of said UGT1A3 allele.

A method for identifying a prostate cancer patient likely to survive death related to prostate cancer for a time longer than 3.5 years, wherein said method comprises:

• (a) detecting the presence of a UGT1A7 allele comprising rs6753320 or rs6736508 in said patient, and
• (b) classifying said patient as being likely to survive death related to prostate cancer a time longer than 3.5 years based at least in part on the presence of said UGT1A7 allele.

A method for identifying a prostate cancer patient likely to survive death related to prostate cancer for a time longer than 3.5 years, wherein said method comprises:

• (a) detecting the presence of two UGT1A10 alleles comprising a wild-type sequence at the rs10929251 or rs10929252 SNP position in said patient, and
• (b) classifying said patient as being likely to survive death related to prostate cancer a time longer than 3.5 years based at least in part on the presence of said two UGT1A10 alleles.

A method for identifying a prostate cancer patient likely to survive death related to prostate cancer for a time shorter than 3.0 years, wherein said method comprises:

• (a) detecting the presence of a UGT1A10 allele comprising rs10929251 or rs10929252 in said patient, and
• (b) classifying said patient as being likely to survive death related to prostate cancer for a time shorter than 3.0 years based at least in part on the presence of said UGT1A10 allele.